Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Clinical Research in Southampton
Southampton Children's Hospital
A
A
A
Text only
| Accessibility | Privacy and cookies
"Helpful, informative, polite and friendly staff put my mind at ease"
Patient feedback
Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us
You are here:
Home
>
Search results
Search
Browse site A to Z
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Search results
Go To Simple Search
Search Type:
Include the phrase
Include any of the words
Criteria:
You could also try:
procedure (653)
,
etiquette (1)
,
practice (614)
Atezolizumab-Carboplatin(AUC5)-Etoposide(IV/PO)
Description
Chemotherapy
Protocol
LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen Lung - Atezolizumab-Carboplatin (AUC5)-Etoposide(IV/PO
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-CarboplatinAUC5-EtoposideIVPO.pdf
BV-CHP Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Ver1
Description
Chemotherapy
Protocol
LYMPHOMA BRENTUXIMAB VEDOTIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE (BV-CHP) Regimen • Lymphoma – Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Indication Brentuximab vedotin in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BV-CHP-Brentuximab-vedotin-cyclophosphamide-doxorubicin-prednisolone.pdf
Annual report 15-16
Description
University Hospital Southampton NHS Foundation Trust Annual report and accounts 2015/16 incorporating the quality account 2015/16 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-15-16.pdf
Atezolizumab-Bevacizumab
Description
Chemotherapy
Protocol
Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen HCC-Atezolizumab-Bevacizumab Indication Atezolizumab in combination with bevacizumab for the first-line systemic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf
MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1
Description
Chemotherapy
Protocol
MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf
Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)
Description
Chemotherapy
Protocol
RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf
RPMitCEBO-Bleomycin-Cyclophosphamide-Etoposide-Mitoxantrone-Prednisolone-Rituximab-Vincristine Ver 1.4
Description
Chemotherapy
Protocol
LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-ETOPOSIDE-MITOXANTRONE-PREDNISOLONERITUXIMAB-VINCRISTINE (RPMitCEBO) Regimen Lymphoma – RPMitCEBO-Bleomycin-Cyclophosphamide-Etoposide-MitoxantronePrednisolone-Rituximab-Vincristine Indication CD20
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RPMitCEBO-Bleomycin-Cyclophosphamide-Etoposide-Mitoxantrone-Prednisolone-Rituximab-Vincristine-Ver-1.4.pdf
RPACEBOM - Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine
Description
Chemotherapy
Protocol
LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-METHOTREXATEPREDNISOLONE-RITUXIMAB-VINCRISTINE Regimen (RPACEBOM) Lymphoma – RPACEBOM-Bleomycin-Cyclophosphamide-Doxorubicin-EtoposideMethotrexate-Prednisolone-Rituximab-Vincristine
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RPACEBOM-Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine.pdf
RGCVP-Cyclophosphamide-Gemcitabine-Prednisolone-Rituximab-Vincristine Ver 1.2
Description
Chemotherapy
Protocol
LYMPHOMA CYCLOPHOSPHAMIDE-GEMCITABINE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RGCVP) Regimen Lymphoma–RGCVP-Cyclophosphamide-Gemcitabine-Prednisolone-RituximabVincristine Indication CD20 positive Non-Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGCVP-Cyclophosphamide-Gemcitabine-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf
MyelomaBortezomib SC DexamethasonePabinostatThalidomide 21day Ver1.1
Description
Chemotherapy
Protocol
MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (SC)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf
611
to
620
of
698
Previous
…
60
61
62
63
64
…
Next
Site policies
Report a problem with this page
Privacy and cookies
Site map
Translation
Last updated: 14 September 2019
Contact details
University Hospital Southampton NHS Foundation Trust
Tremona Road
Southampton
Hampshire
SO16 6YD
Telephone: 023 8077 7222
Useful links
Home
Getting here
What to do in an emergency
Research
Working here
Education
© 2014 University Hospital Southampton NHS Foundation Trust
Browser does not support script.
Browser does not support script.